Ono and Jorna commence research collaboration using AI-based drug discovery platform

小野和乔娜开始使用基于人工智能的药物发现平台进行研究合作

Ono will have an exclusive option right to discover, develop, and commercialize drug candidates generated by the sequences designed by Jorna worldwide

ONO将拥有在全球范围内发现、开发和商业化由Jorna设计的序列生成的候选药物的独家选择权。

Osaka, Japan, April 21, 2025 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has entered into a research collaboration agreement with Jorna Therapeutics (Headquarters: Cambridge, Massachusetts, USA; CEO: Chengwei Luo; “Jorna”) in December 2024 aimed at drug discovery using Jorna's proprietary ribonucleic acid (RNA) editing platform.

日本大阪，2025年4月21日 — 小野药品株式会社（总部：日本大阪；总裁兼首席运营官：泷野十市；“小野药品”）宣布，已于2024年12月与Jorna Therapeutics（总部：美国马萨诸塞州剑桥；首席执行官：罗成伟；“Jorna”）达成研究合作协议，旨在利用Jorna专有的核糖核酸（RNA）编辑平台进行药物发现。

Having completed the validation of this platform, Ono has begun the search for nucleic acid sequences that could serve as drug candidates..

在完成对该平台的验证后，Ono已经开始寻找可作为药物候选物的核酸序列。

Under the agreement, Jorna will design RNA editing drug sequences using its proprietary protein and RNA generative AI model, which is based on the quantum mechanics-based AI called SkyEngine. Ono will have an exclusive option right to discover, develop, and commercialize drug candidates generated by the sequences designed by Jorna worldwide.

根据协议，Jorna 将使用其基于量子力学人工智能 SkyEngine 的专有蛋白质和 RNA 生成 AI 模型设计 RNA 编辑药物序列。Ono 将拥有在全球范围内发现、开发和商业化由 Jorna 设计的序列生成的候选药物的独家选择权。

In addition to the upfront payment already made to Jorna, Ono will also pay for research funding and milestone payments based on the progress of the research..

除了已经向Jorna支付的预付款外，Ono还将根据研究的进展支付研究资金和里程碑款项。

'We highly value Jorna's unique generative AI technologies, which combine large-scale amino acid sequence information and language models to design desired proteins,” said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono. “Through this partnership, we aim to accelerate drug development using RNA editing technology and provide new treatment options to patients around the world with unmet medical needs.'.

“我们高度认可Jorna独特的生成式AI技术，该技术结合了大规模氨基酸序列信息和语言模型来设计目标蛋白质，”小野制药公司董事兼执行官、发现与研究主管桂又史表示。“通过此次合作，我们旨在利用RNA编辑技术加速药物开发，并为全球有未满足医疗需求的患者提供新的治疗选择。”

'We are delighted to collaborate with Ono to advance our shared vision of delivering groundbreaking therapies to patients. This partnership is expected to accelerate efforts to bring RNA editing-based therapies to market by leveraging Ono's global resources and expertise,' said Chengwei Luo, Founder and CEO of Jorna..

“我们很高兴与小野制药合作，推动我们共同的愿景，即为患者提供突破性的疗法。通过利用小野制药的全球资源和专业知识，这一合作伙伴关系有望加速基于RNA编辑的疗法上市进程，”Jorna创始人兼首席执行官罗承伟表示。

About Jorna Therapeutic’s RNA Editing Platform

关于Jorna治疗公司的RNA编辑平台

Jorna's RNA editing platforms, developed using proprietary protein and RNA generative AI models, can efficiently and safely introduce edits to previously inaccessible target RNAs. The AI technology underpinning this platform, known as SkyEngine, analyzes interatomic interactions within and between proteins and small molecules to identify and design sequences.

Jorna的RNA编辑平台是利用专有的蛋白质和RNA生成式AI模型开发的，能够高效且安全地对以前无法触及的目标RNA进行编辑。该平台依托的AI技术名为SkyEngine，可分析蛋白质之间以及蛋白质与小分子之间的原子间相互作用，从而识别并设计序列。

This allows for the precise design of proteins necessary for highly efficient RNA editing..

这使得能够精确设计实现高效 RNA 编辑所需的蛋白质。

About Jorna Therapeutics

关于Jorna Therapeutics

Jorna is a biotechnology company that develops technologies to introduce mutations into target RNA using multiple approaches. By leveraging its proprietary RNA editing technology, designed through AI models and advanced high-throughput systems, Jorna Inc. aims to provide transformative treatments for patients who previously had no therapeutic options.

Jorna是一家生物技术公司，致力于开发通过多种方法将突变引入目标RNA的技术。通过利用其专有的RNA编辑技术（该技术由人工智能模型和先进的高通量系统设计），Jorna公司旨在为以前没有治疗选择的患者提供变革性的治疗方法。

For more information, please visit the company's website at .

如需更多信息，请访问公司网站。

www.jornatx.com

www.jornatx.com

.

。

About Ono Pharmaceutical Co., Ltd.

关于小野药品工业株式会社

Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery.

日本小野药品工业株式会社为全球患者提供创新疗法。秉承“致力于与疾病和痛苦作斗争”的理念，小野药品专注于包括肿瘤学、免疫学和神经学在内的未满足医疗需求的领域，并与学术和生物技术组织合作，加速药物研发。

Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at .

通过其附属公司Deciphera Pharmaceuticals，Ono正在加速在美国和欧洲的临床开发和商业运营，以推动全球业务扩展，并进一步履行对患者护理的承诺。欲了解更多信息，请访问公司网站。

https://www.ono-pharma.com/en

https://www.ono-pharma.com/cn

.

。